Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials

Poly(ADP‐ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first‐in‐class PARP inhibitor, has shown remarkable clinical benefits in the treatment of BRCA‐mutated ovarian or breast cancer. However, the undesirable hematol...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Yang, Changyong, Xie, Chengying, Jiang, Jiahua, Gao, Mingzhao, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398880/
https://www.ncbi.nlm.nih.gov/pubmed/30663191
http://dx.doi.org/10.1111/cas.13947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398880/
https://www.ncbi.nlm.nih.gov/pubmed/30663191
http://dx.doi.org/10.1111/cas.13947

Ejemplares similares